A review of 65 years of human adenovirus seroprevalence

A review of 65 years of human adenovirus seroprevalence

Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types corre...

Full description

Bibliographic Details
Main Authors: Franck J. D. Mennechet, Océane Paris, Aline Raissa Ouoba, Sofia Salazar Arenas, Sodiomon B. Sirima, Guy R. Takoudjou Dzomo, Amidou Diarra, Isidore T Traore, Dramane Kania, Karsten Eichholz, Eric A. Weaver, Edouard Tuaillon, Eric J. Kremer
Format: Article
Language:English
Published: Taylor & Francis Group 2019-06-01
Series:Expert Review of Vaccines
Subjects:
adenovirus
vaccination
gene therapy
immunology
seroepidemiology
Online Access:http://dx.doi.org/10.1080/14760584.2019.1588113

Internet

http://dx.doi.org/10.1080/14760584.2019.1588113

Similar Items